Foreign-Trade Zone (FTZ) 49; Authorization of Production Activity; Merck Sharp & Dohme LLC; (Pharmaceutical Products for Research and Development); Rahway, New Jersey
---
identifier: "/us/fr/2024-15252"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Foreign-Trade Zone (FTZ) 49; Authorization of Production Activity; Merck Sharp & Dohme LLC; (Pharmaceutical Products for Research and Development); Rahway, New Jersey"
title_number: 0
title_name: "Federal Register"
section_number: "2024-15252"
section_name: "Foreign-Trade Zone (FTZ) 49; Authorization of Production Activity; Merck Sharp & Dohme LLC; (Pharmaceutical Products for Research and Development); Rahway, New Jersey"
positive_law: false
currency: "2024-07-11"
last_updated: "2024-07-11"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Commerce Department"
document_number: "2024-15252"
document_type: "notice"
publication_date: "2024-07-11"
agencies:
- "Commerce Department"
- "Foreign-Trade Zones Board"
fr_citation: "89 FR 56848"
fr_volume: 89
docket_ids:
- "B-12-2024"
---
# Foreign-Trade Zone (FTZ) 49; Authorization of Production Activity; Merck Sharp & Dohme LLC; (Pharmaceutical Products for Research and Development); Rahway, New Jersey
On March 8, 2024, Merck Sharp & Dohme LLC submitted a notification of proposed production activity to the FTZ Board for its facility within Subzone 49Y, in Rahway, New Jersey.
The notification was processed in accordance with the regulations of the FTZ Board (15 CFR part 400), including notice in the *Federal Register* inviting public comment (89 FR 19295, March 18, 2024). On July 8, 2024, the applicant was notified of the FTZ Board's decision that no further review of the activity is warranted at this time. The production activity described in the notification was authorized, subject to the FTZ Act and the FTZ Board's regulations, including section 400.14.
Dated: July 8, 2024.
Elizabeth Whiteman,
Executive Secretary.